Aquestive Therapeutics (AQST) Research & Development (2017 - 2026)

Aquestive Therapeutics' Research & Development history runs 10 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Research & Development fell 21.58% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $16.0 million, a 18.64% decrease from a year earlier, with the FY2025 full-year figure at $17.2 million, down 15.23% from the prior year.
• Research & Development advanced to $4.2 million in Q1 2026 per AQST's latest filing, from $3.2 million in the prior quarter.
• Across five years, Research & Development topped out at $5.9 million in Q1 2024 and bottomed at $2.9 million in Q4 2023.
• The 5-year median for Research & Development is $4.2 million (2026), against an average of $4.3 million.
• Across the five-year window, Research & Development soared 70.26% in 2024 and sank 35.0% in 2025, its largest moves.
• Year by year, Research & Development stood at $4.3 million in 2022, then tumbled by 32.49% to $2.9 million in 2023, then soared by 70.26% to $4.9 million in 2024, then sank by 35.0% to $3.2 million in 2025, then soared by 31.54% to $4.2 million in 2026.
• Per Business Quant, the three latest AQST Research & Development figures stand at $4.2 million (Q1 2026), $3.2 million (Q4 2025), and $4.5 million (Q3 2025).